Bioxyma

Bioxyma is a Brazilian biotechnology company specializing in the development of recombinant proteins and innovative biological therapies. Founded in 2008 and headquartered in Araraquara, São Paulo, the company focuses on high-complexity biopharmaceuticals for oncology, hematology, and infectious diseases. Bioxyma is notably involved in the development of the Spike-N-Benz COVID-19 vaccine in collaboration with the University of São Paulo and other partners. Their portfolio includes biosimilars such as Filgrastim, aimed at treating chemotherapy-induced neutropenia. The company leverages its proprietary protein expression platforms to enhance the accessibility of advanced biologics in the Latin American market.